SANTA ROSA, Calif.--(BUSINESS WIRE)--Direct Flow Medical, Inc., [www.directflowmedical.com] a privately held, medical device company developing a next generation, minimally invasive implant to treat patients with heart valve disease, announced today the completion of its Series B financing and the initiation of clinical trials in Europe. The Company has developed a catheter-based system to replace the aortic valve percutaneously in patients with valvular disease. The investigational device is an implantable pericardial tissue valve that allows simple delivery via a transfemoral approach. Its easy positioning (or repositioning) and retrieval features are intended to enable physicians to correctly size and place the device in its targeted location providing a new level of safety for patients. The design also is intended to allow the physician to obtain full hemodynamic data and imaging prior to final device placement.
